Renaissance Technologies
BXRX

Renaissance Technologies’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Renaissance Technologies’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,038
Closed -$59K – 4586
2022
Q3 		$59K Sell
6,038
-1,974
-25% -$45.9K ﹤0.01% 3715
2022
Q2 		$271K Buy
8,012
+2,074
+35% +$96.9K ﹤0.01% 3514
2022
Q1 		$420K Buy
5,938
+5,860
+7,513% +$1.08M ﹤0.01% 3293
2021
Q4 		$24K Buy
+78
New +$48.9K ﹤0.01% 3835
2021
Q1 		– Sell
-302
Closed -$426K – 3864
2020
Q4 		$426K Buy
302
+277
+1,108% +$567K ﹤0.01% 2891
2020
Q3 		$98K Buy
+25
New +$113K ﹤0.01% 3217
2020
Q2 		– Sell
-11
Closed -$37K – 3879
2020
Q1 		$37K Sell
11
-197
-95% -$1.86M ﹤0.01% 3348
2019
Q4 		$2.02M Buy
+208
New +$1.77M ﹤0.01% 2326

Other funds holding BXRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SN
Sittner & Nelson Eugene, Oregon $274M AUM 22.46% 1-Year Est. Return

Renaissance Technologies's BXRX Position: Q4 2022 in Review

Renaissance Technologies sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2022, closing a stake of 6,038 shares — an estimated $59K sold.

Renaissance Technologies first reported a position in BXRX in Q4 2019 and held it in 8 quarters. The position peaked at $2.02M in Q4 2019. 10 funds tracked by Wall St. Rank hold BXRX as of Q4 2022.

  • Renaissance Technologies reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Renaissance Technologies sold 6,038 Baudax Bio, Inc. Common Stock shares in Q4 2022, an estimated $59K.
  • Renaissance Technologies first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
  • Renaissance Technologies's Baudax Bio, Inc. Common Stock position peaked at $2.02M in Q4 2019.
  • 10 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.